# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹611.15 Cr** Q3 (+25%) · **₹1,857 Cr** 9M (+24%) * **EBITDA:** **₹158 Cr** Q3 (+37%) · **₹481 Cr** 9M (+47%) * **EBITDA Margin:** **25%** (last 3 quarters) · **>25%** (9M) * **PAT:** **₹82 Cr** Q3 · **₹232 Cr** 9M (+84%) * Debt/EBITDA: ~1.6x (current), target <2.5x ## B. Revenue Growth * **Resilient Growth Trajectory:** Revenue maintained strong double-digit expansion despite seasonal softness in Q3. * **Seasonal Dynamics:** Q3 dip attributed to **low inventory levels** and **export market closures** around year-end, a recurring pattern observed over four years. ## C. EBITDA & Margins * **Sustained Margin Strength:** EBITDA margins remain robust, with **three consecutive quarters near 25%**, reflecting operational discipline and scale advantages. * **Efficiency Drivers:** Margin resilience supported by **improved process yields**, **lower utility consumption**, and **solar power adoption**, enabling cost control amid stable demand. * **Structural Advantage:** Business model demonstrates insulation from global headwinds due to the **essential nature of aroma chemicals**, enhancing earnings visibility. ## D. Profit After Tax * **Accelerating Bottom-Line Growth:** PAT surged by **84%** over nine months, highlighting strong earnings conversion and structural profitability. * **Profitability Resilience:** Adjusted Q3 PAT more than doubled YoY, underscoring the durability of margins and operational leverage. ## E. Balance Sheet * **Conservative Leverage:** Current **debt/EBITDA at ~6x** remains above target but within historical range; management committed to maintaining **<5x** going forward. --- # 2. Capacity & Expansion ## A. Key Figures * **Capacity Expansion:** **54,000 MT** (post-Phase 1, +6,000 MT) · **+18,000 MT** (Phase 2 & 3, specialty products) · **+20,000 TPA** (corn cobs, new facility) * **Utilization Rate:** **85–90%** current · **Target 90%** on expanded base ## B. Phase 1 Progress * **On-Track Commercialization:** Phase 1 expansion progressing with civil work ~50% complete and detailed engineering advanced, targeting commercial launch by **March–April 2026**. * **Focused Capacity Uplift:** Initial 6,000 MT increase applies only to existing products; multi-specialty chemicals excluded from this phase. * **Strategic Integration:** Amalgamation of Privi Fine Sciences and Privi Biotechnologies into Privi Speciality Chemicals underway, with filings completed. * **Backward Integration Push:** Gujarat facility advancing Furfural integration and value-added production, enhancing cost control and supply security. ## C. Phase 2 & 3 Plans * **Major Capex Underway:** Phase 2, representing bulk of investment, has commenced and targets completion by **Q1 next year**, enabling capacity beyond 54,000 MT. * **High-Margin Specialty Growth:** 18,000 MT expansion dedicated to multi-specialty products under Privi Speciality Chemicals, expected to deliver **Amber Extreme-like margins** due to leveraged overheads. * **Next-Gen Expansion Signaling:** Company plans to announce a **10,000-ton capacity story** before hitting 5,000-ton milestone, indicating aggressive long-term scaling ambitions. ## D. Emerging Growth Initiatives * **Corn Cob Project Scaling:** Technology de-risked and lab-proven; scaling path defined via demonstration → pilot → full production over **12–18 months**, with commercial launch planned for **2028**. * **New Facility in Design:** Two engineering teams actively designing a **20,000-ton-per-annum facility**—unprecedented scale in India—to support commercialization ahead of FY28 launch. * **Cautious Commercialization:** Despite technical confidence, management prioritizing refinement and avoiding overextension; initial stabilization period expected post-launch. --- # 3. Product & Segment Performance ## A. Key Figures * **Cyclopentanone Capacity:** **500 to 5,000 tons** in 2 years * **Target Turnover (Privi Fine Sciences):** **₹400–500 Cr** * **Target Blended Margin:** **>20%** (typically **22–25%**) ## B. Value-Added Products * **Value Over Volume:** Value growth to significantly outpace volume growth, driven by expansion in high-margin value-added products. * **Margin Resilience:** Management expects to sustain current margin levels with continued addition of **high-margin, value-added products** like **Furfural**, to be manufactured in-house post-expansion. ## C. New Molecule Development * **Global Product Ambition:** New molecules—**Ethyl Maltol, Ethylene Brassylate, and bio-based Cyclopentanone**—target global markets with customer approvals and indicative commitments expected upon facility commissioning. * **Innovation Pipeline:** A **new molecule** from cyclopentanone feedstock is in early development, undergoing **1–2 years of lab trials** followed by pilot testing, signaling long-term R&D depth. * **Strategic Differentiation:** Cyclopentanone will be produced via a **first-of-its-kind bio-based, renewable route**, enhancing global competitiveness and sustainability positioning. --- # 4. Capex & Funding ## A. Key Figures * **Capex Plan:** **₹1,200 Cr** over 3 years (Phase 1: **₹300 Cr**, Phase 2: **₹600 Cr**, Phase 3: **₹300 Cr**) * **Total Investment Target:** **₹1,500 Cr** by March 31, 2027 * **Revenue Target:** **₹5,000 Cr** by FY28/FY29 * **State Incentives:** **₹10 Cr** recognized in first 9 months ## B. 3-Year Investment Plan * **Phased Expansion:** Capex execution structured in three clear phases, with completion targeted between March 2027 and March 2028, supporting a major scale-up. * **Strategic Scale-Up:** Investment aims to achieve **ultra mega status**, unlocking long-term structural benefits including extended incentives. ## C. Internal Accruals & Debt * **Funding Mix:** Capex to be funded via internal accruals and bank borrowings, with **leverage below 2x** ensuring no near-term equity dilution. ## D. GST & Incentive Benefits * **Enhanced GST Benefit:** Ultra mega status secures a **9% GST benefit for 20 years** (up from 15), significantly boosting after-tax returns. * **In-State Profitability Boost:** GST benefit **doubles for sales within Maharashtra**, creating a strategic advantage for local market operations. * **Existing Incentives:** Company already benefits from a **7-year state incentive in Gujarat**, though current expansion is focused on higher-scale opportunities. --- # 5. Joint Venture & M&A ## A. Key Figures * **Prigiv Investment:** **INR 50 Cr** equity infusion (51% Privi, 49% Givaudan) * **Givaudan Advance:** **INR 150 Cr** interest-free loan to Prigiv * **Revenue Potential (Post-Merger):** **Up to INR 400 Cr** from Privi Fine Science at optimum capacity ## B. Prigiv Performance * **JV Milestone Achieved:** Prigiv turned EBITDA-positive in Q3, with net profitability expected in the next financial year. * **Capacity & Growth Path:** Manufacturing expansion underway via INR 50 Cr equity funding; scaling a new specialty molecule positions Prigiv for **multi-year growth**. * **Strong Strategic Backing:** Recent equity infusion and interest-free financing reflect deepening commitment from both partners. ## C. Givaudan Commitment * **Financial De-Risking:** INR 150 Cr noninterest-bearing advance from Givaudan to reduce JV debt and bridge standalone-consolidated earnings gap. * **Loss Recovery Confirmed:** Management expects standalone losses to be fully offset next year due to improved performance and financing support. * **Incremental Growth Upside:** Prigiv’s contributions are excluded from the current ₹5,000 Cr revenue roadmap—future revenues will be additive. ## D. Merger Timeline * **Merger Completion Expected:** Privi Fine Science merger slated between **October–December 2026**, subject to NCLT approval. * **Financial Integration:** Merged entity’s results to be reflected by **FY27 at latest**, no later than FY28. * **Integrated Capacity Planning:** No standalone expansion of Privi Fine Speciality; future capacity to be managed under merged structure. --- # 6. Export & Geography Mix ## A. Key Figures * **Export Sales Mix:** **70%** of total sales · **30%** spot market exposure * Forex Benefit: INR 3.5 Cr income from INR depreciation (current quarter) * **Duty Advantage:** Up to **18%** tariff benefit in key markets, with **0% duty** on select products ## B. Global Trade Positioning * **Strategic Export Advantage:** Strong alignment with de-risking trends as developed markets prioritize **reliable, diversified, and compliant supply chains**, boosting Privi’s competitiveness vs. China. * **Favorable Trade Dynamics:** Recent **C. S. tariff removal (25%)** and **EU treaty developments** enhance market access and pricing power in key geographies. ## C. Long-Term Contracting & Policy Tailwinds * **Revenue Visibility:** High proportion of sales under **long-term contracts** ensures stability and reduces exposure to commodity volatility. * **Future Carbon Edge:** Anticipated **duty benefits in U.S. and Europe** within 1–3 years due to lower carbon footprint, once CBAM and green trade policies regain momentum. --- # 7. Risks & Regulatory ## A. CBAM & Regulatory Advantage * **Favorable CBAM Positioning:** Set to gain significant competitive advantage under EU’s Carbon Border Adjustment Mechanism from 2026, leveraging near-zero carbon footprint and EcoVadis platinum rating. * **Commercial Edge in Europe:** Platinum sustainability rating enhances credibility and commercialization prospects in regulated European markets. * **Market Share Upside:** Structural advantage from low embedded carbon emissions positions the company for potential **increased market share** as carbon costs impact global peers. * **Switzerland Clarity Pending:** Regulatory uncertainty remains over Switzerland’s CBAM participation, a key consideration given its importance as a major customer. ## B. Global Market & Guidance Stance * **Cautious Outlook:** Maintains conservative guidance despite positive trends, citing persistent **VUCA conditions** in the global macro and trade environment. * **Customer-Centric Focus:** Leadership reaffirms priority on customer satisfaction, with confidence in current client relationships. --- # 8. Guidance & Outlook ## A. Key Figures * **EBITDA Margin:** **25%+** achieved for 3 consecutive quarters · **20%+** sustained outlook (fluctuations expected between **23–25%**, below **27%**) * **Volume Growth:** **~7%** projected based on current capacity · **11–15%** potential with new projects * **EBITDA Target:** **₹1,000 Cr** aligned with ₹5,000 Cr revenue goal ## B. 20%+ Margin Target * **Sustained Margin Strength:** EBITDA margins expected to remain **above 20%** driven by operational efficiencies, improved product mix, and volume leverage despite global headwinds. * **Margin Ceiling Acknowledged:** Management cautions against expectations of **25%+ as guaranteed**, citing macro uncertainties; gross margin expansion limited to **100–200 bps** over several years. ## C. INR5,000 Cr Revenue Goal * **Multi-Year Scaling Pathway:** Clear strategic roadmap to reach **₹5,000 Cr revenue** and **₹1,000 Cr EBITDA** by FY '29, supported by Cyclopentanone and value-added product growth. * **Phased Growth Execution:** FY '28 to be a **transition year** for capacity optimization; **FY '29** expected to deliver a **major revenue inflection** and scaling step-up. ## D. C * **Expectations Management:** Investor benchmarks have created **high performance expectations**, making consistent delivery perceptionally challenging despite strong execution.